Indegene IPO
Indegene Limited provide digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Their solutions enable life sciences companies to develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. They achieve this by combining over two decades of healthcare domain expertise and fit-for-purpose technology. Their portfolio of solutions cover all aspects of commercial, medical, regulatory and R&D operations of life sciences companies.
They have established client relationships with each of the 20 largest biopharmaceutical companies in the world by revenue for the Financial Year 2023 (Source: Everest Report), having earned more than 69.00% of their total revenue from operations for each of the nine months ended December 31, 2023 and 2022 and the Financial Years 2023, 2022 and 2021 from these 20 customers. As of December 31, 2023, they had a total of 65 active clients.
Positioned at the intersection of healthcare and technology, their solutions span across different stages of the commercialization lifecycle of drugs and medical devices. Their Enterprise Commercial Solutions and their Omnichannel Activation solutions cater to the commercial functions of life sciences companies while their Enterprise Medical Solutions and Enterprise Clinical Solutions cater to their medical and R&D functions.
As of December 31, 2023, they had 65 active clients. They deliver solutions to them from their operation hubs located across North America, Europe and Asia. They have internally developed artificial intelligence (“AI”) and machine learning (“ML”) based proprietary platforms, which allow them to offer their solutions across the globe at scale. Their delivery model allows them to operate where their clients are located. As of December 31, 2023, they had 5,181 full-time employees across 10 countries, of which 4,510 employees were delivery employees (i.e., employees who do not belong to corporate and support functions). As of December 31, 2023, 20.49% of their delivery employees had healthcare-related educational backgrounds.
Note: The actual amount will be debited when the shares are allotted to you.
Note: The actual amount will be debited when the shares are allotted to you.
An IPO offers share market participants like you and me an opportunity to be a shareholder in an erstwhile privately held company that is now going public and being listed on the market. Historically speaking, investors who choose the right IPOs make significant returns on their investments, which increases the attraction of IPOs.
Once you are a shareholder, you are eligible to receive dividends from the company proportional to the shares you own. You can also sell your stocks for profit on the stock exchange.
In exchange for its shares, the company has an opportunity to raise huge capital to be used to further enhance its business and scale up its operations. The company also has other benefits, such as credibility; visibility; better leverage to effect mergers, acquisitions and even to procure loans at lower rates of interest.
In India, the entire IPO process is ably regulated by the Securities & Exchange Board of India (SEBI), right from the IPO filing by the company to the bidding, allotments and refunds (in case you aren't allotted shares due to oversubscription).
Don't have a Sharekhan account?
Open demat account in 15 mins*!
